Roth Capital lowered the firm’s price target on MGP Ingredients (MGPI) to $32 from $41 and keeps a Buy rating on the shares. The company’s Q4 results exceeded guidance, the firm’s estimates, and consensus, but its 2026 outlook shows that MGP is still at least several quarters away from showing y/y improvements, the analyst tells investors in a research note. Roth adds however that the stock’s current valuation overstates the level of risk facing investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGPI:
- MGP Ingredients Earnings Call: Premium Wins, Tough 2026
- MGP Ingredients reports Q4 adjusted EPS 63c, consensus 50c
- MGP Ingredients sees FY26 adjusted EPS $1.50-$1.80, consensus $2.44
- MGPI Upcoming Earnings Report: What to Expect?
- Benchmark starts MGP Ingredients at Buy as company responds to challenges